Understanding Leukemogenesis: Challenges and Advancements in Diagnostic Approaches


Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 03 | Issue : 01 | Page : –
    By

    Brian Ndubi,

  1. Student, Program BMLT, SSAHS, Sharda University, Uttar Pradesh, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_174943’);});Edit Abstract & Keyword

Leukaemia development, or leukemogenesis, is a multifactorial process driven by a complex interplay of environmental, genetic, and epigenetic factors. Despite substantial advancements in technology and medicine, which have enhanced our understanding of the contributing factors, early and accurate diagnosis remains a major challenge due to the overlapping clinical features shared by the various leukaemia subtypes. This study explores the molecular and cellular mechanisms underlying leukemogenesis, while also addressing the difficulties in distinguishing between leukaemia subtypes. Furthermore, it reviews the current diagnostic procedures and evaluates the role of emerging technologies and tools that hold promise for improving diagnostic precision. The inherent variability of leukaemia, combined with its numerous subtypes, makes accurate diagnosis exceedingly difficult, even in light of recent strides in elucidating the molecular pathways involved in leukemogenesis. The presence of measurable residual disease (MRD) further complicates the assessment of treatment response and the prediction of relapse. Additionally, substantial inter- and intratumoral heterogeneity adds layers of complexity in identifying consistent diagnostic biomarkers. One of the most significant challenges lies in the identification of reliable biomarkers capable of distinguishing between patients who respond to therapy and those who do not. Recent advances in next-generation sequencing (NGS) and genomic profiling have greatly expanded our knowledge of the genetic underpinnings of leukaemia, yet translating these findings into clinical practice remains problematic. The challenge persists in applying these discoveries effectively within the diagnostic and therapeutic landscape. This abstract underscore the urgent need for continued research aimed at developing more precise, personalized diagnostic tools. Such advancements are critical not only to enhance early diagnosis but also to improve treatment outcomes and enable more effective management of leukaemia patients.

Keywords: Leukaemia, Inherent, Treatment, Biomarkers, Diagnosis

[This article belongs to International Journal of Biomedical Innovations and Engineering (ijbie)]

How to cite this article:
Brian Ndubi. Understanding Leukemogenesis: Challenges and Advancements in Diagnostic Approaches. International Journal of Biomedical Innovations and Engineering. 2025; 03(01):-.
How to cite this URL:
Brian Ndubi. Understanding Leukemogenesis: Challenges and Advancements in Diagnostic Approaches. International Journal of Biomedical Innovations and Engineering. 2025; 03(01):-. Available from: https://journals.stmjournals.com/ijbie/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_174943’);});Edit

References

  1. Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Am J Hematol. 2024;99(7):1360-1387.
  2. Karunarathna I, De Alvis K, Gunasena P, Jayawardana A. Leukemia: Classification, risk factors, and diagnostic challenges. 2024.
  3. Ally F, Chen X. Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry. Cancers. 2024;16(22):3855.
  4. Zhao W. Applications of Molecular Genetic Testing in Hematopoietic and Lymphocytic Neoplasms. J Clin Transl Pathol. 2024;4(4):153-162.
  5. Marando L, Csizmar CM, Patnaik MM. Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica. 2024;110(1):22.
  6. Tsilingiris D, Vallianou NG, Spyrou N, Kounatidis D, Christodoulatos GS, Karampela I, et al. Obesity and leukemia: biological mechanisms, perspectives, and challenges. Curr Obes Rep. 2024;13(1):1-34.
  7. Kaur G, Prakash A, Medhi B. Cytokine Analysis in Leukemia and Minimal Residual Disease (MRD) Detection Through Flow Cytometry. In: Flow Cytometry: Principles, Applications, and Clinical Perspectives. Singapore: Springer Nature Singapore; 2024. p. 289-97.
  8. Liu YC, Geyer JT. Pediatric Hematopathology in the era of advanced molecular diagnostics: what we know and how we can apply the updated classifications. Pathobiology. 2024;91(1):30-44.
  9. Zhang H, Xia J, Wang X, Wang Y, Chen J, He L, et al. Recent Progress of Exosomes in Hematological Malignancies: Pathogenesis, Diagnosis, and Therapeutic Strategies. Int J Nanomedicine. 2024;19:11611-31.
  10. Prajapati SK, Kumari N, Bhowmik D, Gupta R. Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia. Ann Hematol. 2024;103(11):4375-400.
  11. Afzal M, Sharma A, Sah AK, Chahal A. Structural and functional alterations in hematological parameters among individuals at clinically high risk for acute lymphocytic leukemia. Iraqi J Hematol. 2024;13(2):159-69.
  12. Jaiswal G, Dubey R, Prajapati KK. Leukemia its origin, types, risk factors and survivorship. World J Biol Pharm Health Sci. 2024;18(1):283-92.
  13. Achir A, Debbarh I, Zoubir N, Battas I, Medromi H, Moutaouakkil F. Advances in Leukemia detection and classification: A Systematic review of AI and image processing techniques. F1000Res. 2024;13:1536.
  14. Balciuniene J, Ning Y, Lazarus HM, Aikawa V, Sherpa S, Zhang Y, et al. Cancer cytogenetics in a genomics world: Wedding the old with the new. Blood Rev. 2024;101209.
  15. Costa A, Scalzulli E, Breccia M. Chronic eosinophilic leukaemia—Not otherwise specified: Clinical features, genomic insight and therapeutic strategies. Br J Haematol. 2024.
  16. Singh AP, Saxena R, Saxena S. Plasma apheresis procedure. EPRA Int J Multidiscip Res. 2022;8(7):205-18.
  17. AlAnazi N, AlMukhaylid S, Iqbal Z. Innovations in pathophysiology, diagnosis, genomic medicine and state-of-the-art treatment approaches in pediatric acute lymphoblastic leukemia in the twenty-first century. 2024.
  18. Singh AP, Maurya NK, Saxena R, Saxena S. An overview of red blood cell properties and functions. J Int Res Med Pharm Sci. 2024;19(2):14-23.
  19. Singh AP, Saxena R, Saxena S. Cytopathology: an important aspect of medical diagnosis. Res Rev J Oncol Hematol. 2023;12(3):13-18.
  20. El Mahdaoui C, Dehbi H, Cherkaoui S. A review of emerging cytogenetic and molecular approaches in identifying abnormalities in acute lymphoblastic leukemia. 2024.
  21. Chaudhary S, Chaudhary P, Ahmad F, Arora N. Acute myeloid leukemia and next-generation sequencing panels for diagnosis: a comprehensive review. J Pediatr Hematol Oncol. 2024;46(3):125-37.
  22. Singh AP, Batra J, Saxena R, Saxena S. Susceptibility to cervical cancer: an overview. 2024.
  23. Chen X, Wood BL. Acute myeloid leukemia: diagnosis and measurable residual disease detection by flow cytometry. In: Manual of Molecular and Clinical Laboratory Immunology. 2nd ed. 2024. p. 1180-92.
  24. Yousefnia S, Negahdary M. Diagnostic application of aptamers against leukemia, multiple myeloma and lymphoma: a review. J Drug Deliv Sci Technol. 2024;106103.
  25. Singh AP, Batra J, Khan SS, Saxena R, Saxena S. Diagnosis and treatment of Wilson disease: an update. Cardiometry. 2022;(25):1397-400.
  26. Rahman HA, Singh AP. Section cutting in histopathology: an update. Res Rev J Health Prof. 2024;14(1):29-34.
  27. Alanazi N, Siyal A, Basit S, Shammas M, Al-Mukhaylid S, Aleem A, et al. Clinical validation of the somatic FANCD2 mutation (c.2022-5C>T) as a novel molecular biomarker for early disease progression in chronic myeloid leukemia: a case–control study. Hematol Rep. 2024;16(3):465-78.
  28. AlAnazi N, AlMukhaylid S, Iqbal Z. Innovations in pathophysiology, diagnosis, genomic medicine and common childhood diseases: diagnosis, prevention and management. 2024;157.
  29. AlAnazi N, AlMukhaylid S, Iqbal Z. Innovations in pathophysiology, diagnosis, genomic medicine and common childhood diseases: diagnosis, prevention and management. 2024;157.
  30. Singh AP, Saxena R, Saxena S, Maurya NK. Mind unveiled: cutting-edge neuroscience and precision brain mapping. Asian J Curr Res. 2024;9(3):181-95.
Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 24/01/2025
Accepted 28/01/2025
Published 21/02/2025
Publication Time 28 Days
183

async function fetchCitationCount(doi) {
let apiUrl = `https://api.crossref.org/works/${doi}`;
try {
let response = await fetch(apiUrl);
let data = await response.json();
let citationCount = data.message[“is-referenced-by-count”];
document.getElementById(“citation-count”).innerText = `Citations: ${citationCount}`;
} catch (error) {
console.error(“Error fetching citation count:”, error);
document.getElementById(“citation-count”).innerText = “Citations: Data unavailable”;
}
}
fetchCitationCount(“10.37591/IJBIE.v03i01.0”);

Loading citations…